Quantcast

Latest Monoclonal antibodies Stories

2014-06-28 09:28:48

University of Texas Medical Branch at Galveston Human antibody therapy successfully combats virus 5 days after infection An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences and three groups within the National Institutes of Health reports a new breakthrough in countering the deadly Nipah virus. The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for...

2014-06-26 12:29:42

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Moduleshttp://www.reportbuyer.com/pharma_healthcare/diseases/multiple_sclerosis_kol_insight_consensus_outlook_modules.html IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market...

2014-06-25 08:32:07

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive...

2014-06-24 08:29:37

CAMBRIDGE, England, June 24, 2014 /PRNewswire/ -- Sphere Fluidics Limited has developed unique technology for single cell analysis and characterization, and provides proprietary products and novel services for this rapidly-growing market. The Company has now just secured $2.3 million in a First Close of a new investment round. The latter will finally complete in early September 2014 with more potential funding already in the pipeline. "This is the first tranche of funding that...

2014-06-23 12:29:04

AUSTIN, Texas, June 23, 2014 /PRNewswire/ -- XBiotech announced today that Gary Gonzales has joined the Company as Vice President of Clinical Operations. Mr. Gonzales will lead XBiotech's clinical trial team and manage the Company's international clinical operations. Mr. Gonzales joins XBiotech from INC Research where he managed large, global pivotal phase III trials. Mr. Gonzales has B.S. & M.S. degrees in chemistry and biology and also holds a M.B.A. Mr. Gonzales comes to...

2014-06-19 09:35:10

The JAMA Network Journals In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA. Tumor necrosis factor α (TNF-α)...

2014-06-18 23:16:14

Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Portland, Maine (PRWEB) June 18, 2014 Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding...

2014-06-16 12:29:02

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO((TM) )(vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). "We understand how a great need still exists for additional treatment options...

2014-06-12 23:04:03

Ion Exchange Chromatography Reagents market can be segmented by Companies, Geographies, Applications, Products, Technologies and End Users. http://www.micromarketmonitor.com/market-report/ion-exchange-chromatography-reagents-reports-9812782514.html (PRWEB) June 12, 2014 The global ion exchange chromatography reagents market is projected to grow at a CAGR of about 11.0% from 2013 to 2018. Increased support from governments’ worldwide, increased usage of chromatographic techniques in the...

2014-06-11 23:13:29

New England Peptide and SISCAPA expand commercialization of mass spec biomarker assays. Gardner, MA (PRWEB) June 11, 2014 Today, New England Peptide, Inc. (NEP) and SISCAPA Assay Technologies, Inc. (SAT) announced a collaboration for the manufacture and sale of Stable Isotope Standard (SIS) peptides for use in SISCAPA® protein quantification assays. Under the terms of the agreement, NEP will manufacture peptide standards suitable for use with SAT’s SISCAPA assays. The peptides will...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related